JP2017506265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506265A5 JP2017506265A5 JP2016570917A JP2016570917A JP2017506265A5 JP 2017506265 A5 JP2017506265 A5 JP 2017506265A5 JP 2016570917 A JP2016570917 A JP 2016570917A JP 2016570917 A JP2016570917 A JP 2016570917A JP 2017506265 A5 JP2017506265 A5 JP 2017506265A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic
- poly
- immunogenic composition
- methacrylic acid
- enteric coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 76
- 239000002702 enteric coating Substances 0.000 claims description 40
- 238000009505 enteric coating Methods 0.000 claims description 40
- 229920001577 copolymer Polymers 0.000 claims description 28
- 239000003124 biologic agent Substances 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 18
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 17
- 239000000454 talc Substances 0.000 claims description 17
- 229910052623 talc Inorganic materials 0.000 claims description 17
- 239000001069 triethyl citrate Substances 0.000 claims description 17
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 17
- 235000013769 triethyl citrate Nutrition 0.000 claims description 17
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 210000003405 ileum Anatomy 0.000 claims description 10
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims description 9
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 9
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 7
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 16
- 238000000034 method Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- -1 for example Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942386P | 2014-02-20 | 2014-02-20 | |
| US61/942,386 | 2014-02-20 | ||
| PCT/US2015/016921 WO2015127278A1 (en) | 2014-02-20 | 2015-02-20 | Formulations for small intestinal delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191383A Division JP7168633B2 (ja) | 2014-02-20 | 2020-11-18 | 小腸送達のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506265A JP2017506265A (ja) | 2017-03-02 |
| JP2017506265A5 true JP2017506265A5 (enExample) | 2018-03-29 |
| JP6797692B2 JP6797692B2 (ja) | 2020-12-09 |
Family
ID=53879055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570917A Active JP6797692B2 (ja) | 2014-02-20 | 2015-02-20 | 小腸送達のための製剤 |
| JP2020191383A Active JP7168633B2 (ja) | 2014-02-20 | 2020-11-18 | 小腸送達のための製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191383A Active JP7168633B2 (ja) | 2014-02-20 | 2020-11-18 | 小腸送達のための製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170224805A1 (enExample) |
| EP (2) | EP4353255A3 (enExample) |
| JP (2) | JP6797692B2 (enExample) |
| KR (1) | KR102396817B1 (enExample) |
| CN (1) | CN106255508B (enExample) |
| AU (1) | AU2015218769B2 (enExample) |
| CA (1) | CA2939581C (enExample) |
| DK (1) | DK3107568T3 (enExample) |
| EA (1) | EA033248B1 (enExample) |
| ES (1) | ES2978921T3 (enExample) |
| IL (1) | IL247301B (enExample) |
| SG (1) | SG11201606814RA (enExample) |
| WO (1) | WO2015127278A1 (enExample) |
| ZA (1) | ZA201605787B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2832504T3 (es) | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
| CA3046019A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| KR20190104051A (ko) * | 2017-01-06 | 2019-09-05 | 스타빌리테크 바이오파마 리미티드 | 바이러스 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152413A (en) * | 1978-08-18 | 1979-05-01 | Chromalloy American Corporation | Oral vaccine for swine dysentery and method of use |
| US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| CA2110899C (en) * | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| WO1994015635A1 (en) | 1993-01-11 | 1994-07-21 | Dana-Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6676935B2 (en) * | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
| AUPO856097A0 (en) * | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| GB9818591D0 (en) * | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
| US7264771B2 (en) | 1999-04-20 | 2007-09-04 | Baxter International Inc. | Method and apparatus for manipulating pre-sterilized components in an active sterile field |
| US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| JP2004504264A (ja) * | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化 |
| AU2003240978A1 (en) | 2002-05-31 | 2003-12-19 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
| AU2003262922A1 (en) | 2002-08-30 | 2004-03-19 | Genteric, Inc. | Retroductal salivary gland genetic vaccination |
| GB2407500A (en) * | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Use of microparticles for antigen delivery |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| EA014757B1 (ru) | 2006-02-28 | 2011-02-28 | Вэксарт, Инк. | Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота |
| JP2009298707A (ja) * | 2008-06-11 | 2009-12-24 | Ohara Yakuhin Kogyo Kk | 粒子加工方法 |
| JP2011526888A (ja) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| WO2011026111A1 (en) * | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| DK2477652T3 (en) | 2009-09-16 | 2015-07-20 | Vaxart Inc | Immunization strategy for the prevention of infection H1Ni |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| CN110152000A (zh) * | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| CA3008794C (en) * | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| EP3549605A1 (en) * | 2012-04-04 | 2019-10-09 | Vaxform LLC | Adjuvant system for oral vaccine administration |
-
2015
- 2015-02-20 CA CA2939581A patent/CA2939581C/en active Active
- 2015-02-20 EP EP24158414.3A patent/EP4353255A3/en not_active Withdrawn
- 2015-02-20 AU AU2015218769A patent/AU2015218769B2/en active Active
- 2015-02-20 EP EP15752216.0A patent/EP3107568B1/en active Active
- 2015-02-20 US US15/120,069 patent/US20170224805A1/en not_active Abandoned
- 2015-02-20 IL IL247301A patent/IL247301B/en unknown
- 2015-02-20 DK DK15752216.0T patent/DK3107568T3/da active
- 2015-02-20 JP JP2016570917A patent/JP6797692B2/ja active Active
- 2015-02-20 WO PCT/US2015/016921 patent/WO2015127278A1/en not_active Ceased
- 2015-02-20 EA EA201691458A patent/EA033248B1/ru not_active IP Right Cessation
- 2015-02-20 SG SG11201606814RA patent/SG11201606814RA/en unknown
- 2015-02-20 CN CN201580015312.2A patent/CN106255508B/zh active Active
- 2015-02-20 KR KR1020167024704A patent/KR102396817B1/ko active Active
- 2015-02-20 ES ES15752216T patent/ES2978921T3/es active Active
-
2016
- 2016-08-19 ZA ZA2016/05787A patent/ZA201605787B/en unknown
-
2020
- 2020-11-18 JP JP2020191383A patent/JP7168633B2/ja active Active
-
2024
- 2024-10-11 US US18/913,437 patent/US20250032602A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521030A5 (enExample) | ||
| ES2655622T3 (es) | Una formulación de fármaco de liberación retardada | |
| HRP20230305T1 (hr) | Pripravci za ileo-jejunalnu dostavu lijeka | |
| JP2018500353A5 (enExample) | ||
| JP2016517425A5 (enExample) | ||
| JP5847303B2 (ja) | 医薬品剤形又は機能性食品剤形に適したコーティング組成物 | |
| JP5167345B2 (ja) | 薬剤を加速放出する腸溶コーティングを含む固体剤形 | |
| Jain et al. | Expedition of Eudragit® polymers in the development of novel drug delivery systems | |
| BG105061A (bg) | Ентерично покрит фармацевтичен състав и метод за получаване | |
| US9668977B2 (en) | Coating composition suitable for pharmaceutical or nutraceutical dosage forms | |
| JP2016532655A5 (enExample) | ||
| NO20052860L (no) | Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme | |
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| JP2009504710A5 (enExample) | ||
| JP2009102335A (ja) | 胃腸障害を処置するための剤形 | |
| EP2283830A1 (en) | Aqueous enteric capsule coating | |
| US20210205230A1 (en) | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | |
| MA34768B1 (fr) | Comprimé orodispersible | |
| NZ604646A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| JP2017506265A5 (enExample) | ||
| JP2014208655A5 (enExample) | ||
| JPWO2017022248A1 (ja) | 腸溶性カプセル | |
| JP2015512441A5 (enExample) | ||
| JP2020063295A (ja) | 放出調節コーティングカプセル | |
| JP2007524646A (ja) | 膨潤可能なコーティングを有する薬学的組成物 |